AI Earnings Predictions for Mirion Technologies Inc. (MIR)

EX-99.1

2 a2026-07x28exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Second Quarter 2026 Financial Results

•Revenues for the second quarter increased 19.7% to $266.8 million, compared to $222.9 million in the same period in 2025.

•GAAP net income was $8.1 million in the second quarter, a 4.7% decrease compared to GAAP net income of $8.5 million in the same period in 2025; Adjusted EBITDA was $65.3 million in the second quarter, a 27.5% increase from $51.2 million in the same period last year.

•GAAP net earnings per share in the second quarter was $0.03, compared to $0.04 in the same period in 2025. Adjusted earnings per share for the quarter was $0.12, compared to $0.11 in the same period in 2025. The current period calculation of Adjusted EPS includes stock based compensation expense.

•Second quarter orders, excluding Paragon & Certrec acquisitions, were $229 million, a 10% increase from $208 million in the same period last year. Including Paragon and Certrec acquisitions, second quarter orders were $291 million, a 40% increase compared to the same period last year.

•The company reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

Atlanta, GA – July 28, 2026 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the second quarter ended June 30, 2026.

“Our second quarter performance reflects margin expansion across both operating segments, increased adjusted free cash flow, and continued orders and backlog growth,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “We captured several large opportunity orders in the second quarter with substantial opportunity available for the rest of the year.”

Logan continued, “Our acquisitions of Certrec and Paragon have augmented our ability to capitalize on growing nuclear power opportunities in North America. Moreover, our global presence puts us at the forefront of international nuclear growth ambitions.”

2026 Guidance

Commenting on Mirion’s full year 2026 guidance, Logan said, “We remain well-positioned for second half 2026 accelerated revenue growth, adjusted free cash flow, and margin expansion. We are maintaining our full year 2026 guidance while adjusting the end-market composition of our Medical segment.”

Mirion reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

•Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.

•Organic Revenue growth of approximately 5.0% – 7.0%.

•Adjusted EBITDA and Adjusted EBITDA margin of approximately $285 million – $300 million; Adjusted EBITDA margin of approximately 25.0% – 26.0%.

•Adjusted Free Cash Flow of approximately $155 million – $175 million; Adjusted Free Cash Flow Conversion of approximately 54% – 58% of Adjusted EBITDA.

•Adjusted EPS of approximately $0.48 – $0.55 per share.

Exhibit 99.1

News Release

Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for Organic Revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Adjusted Free Cash Flow and Adjusted Free Cash Flow conversion are not available without unreasonable effort.

Conference Call

Mirion will host a conference call tomorrow, July 29, 2026 at 10:00 a.m. ET to discuss its financial results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events.

A telephonic replay will be available shortly after the conclusion of the call and until August 12, 2026. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671, and enter access code 13761513. An a

EX-99.1

2 a2026-04x28exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces First Quarter 2026 Financial Results

•Revenues for the first quarter increased 27.5% to $257.6 million, compared to $202.0 million in the same period in 2025.

•GAAP net loss was $3.4 million in the first quarter, compared to GAAP net income of $0.4 million in the same period in 2025; Adjusted EBITDA was $54.3 million in the first quarter, a 16.3% increase from $46.7 million in the same period last year.

•GAAP net loss per share in the first quarter was $0.01, compared to a GAAP net earnings per share of $0.00 in the same period in 2025. Adjusted earnings per share for the quarter was $0.10, compared to $0.10 in the same period in 2025. The calculation for adjusted earnings per share has been adjusted for the current period to include stock-based compensation.

•First quarter orders, excluding Paragon & Certrec acquisitions, were $241 million, a 19% increase from $203 million in the same period last year. Including Paragon and Certrec acquisitions, first quarter orders were $288 million, a 42% increase compared to the same period last year.

•The company reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance for the fiscal year ending December 31, 2026, while revising Adjusted EPS guidance to reflect the impact of a special one-time CEO retention grant of performance vesting stock options disclosed on April 13, 2026.

Atlanta, GA – April 28, 2026 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the first quarter ended March 31, 2026.

“Our first quarter performance showcased substantial orders growth led by nuclear power demand and as-expected Adjusted EBITDA performance and margins,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “Record capital spending commitments by power plant operators are driving accelerating momentum in the sector, which is translating into significant Nuclear Power demand.”

Logan continued, “Our strong performance also reflects Paragon’s contributions in its first full quarter with Mirion. Paragon is the ‘tip of the spear’ for growing installed base dynamics. Integration is on-pace, and we are already realizing commercial synergies.”

2026 Guidance

Commenting on Mirion’s full year 2026 guidance, Logan said, “We remain on track for 2026 revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance. Our business continues to capture momentum in Nuclear Power and Cancer Care markets. Additionally, we are bringing new products to market and enhancing our current offerings to meet customers where they are headed.”

Mirion reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance for the fiscal year ending December 31, 2026, while revising Adjusted EPS guidance to reflect the impact of a special one-time CEO retention grant of performance vesting stock options disclosed on April 13, 2026.

•Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.

•Organic Revenue growth of approximately 5.0% – 7.0%.

•Adjusted EBITDA and Adjusted EBITDA margin of approximately $285 million – $300 million; Adjusted EBITDA margin of approximately 25.0% – 26.0%.

Exhibit 99.1

News Release

•Adjusted Free Cash Flow of approximately $155 million – $175 million; Adjusted Free Cash Flow Conversion of approximately 54% – 58% of Adjusted EBITDA.

•Adjusted EPS of approximately $0.48 – $0.55 per share (previously $0.50 – $0.57 per share); adjusted to reflect the impact of a special one-time CEO retention grant of performance vesting stock options disclosed on April 13, 2026.

Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for Organic Revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Adjusted Free C

EX-99.1

2 a2026-02x10exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Fourth Quarter and Full Year 2025 Financial Results; Provides Full Year 2026 Guidance

•Revenues for the fourth quarter increased 9.1% to $277.4 million, compared to $254.3 million in the same period in 2024.

•GAAP net income was $17.8 million in the fourth quarter, compared to a GAAP net income of $15.9 million in the same period in 2024, an 11.9% improvement. Adjusted EBITDA was $77.6 million, an 11.5% increase from $69.6 million in the same period in 2024.

•GAAP net earnings per share in the fourth quarter was $0.07, compared to a GAAP net earnings per share of $0.07 in 2024. Adjusted earnings per share for the quarter was $0.15, compared to $0.17 in the same period in 2024.

•The company announced its full year 2026 guidance for revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted Earnings per Share.

◦Total Revenue growth rate is expected to be between 22.0% and 24.0%.

◦Organic Revenue growth rate is expected to be between 5.0% and 7.0%.

◦Adjusted EBITDA is expected to be between $285 million and $300 million.

◦Adjusted Free Cash Flow is expected to be between $155 and $175 million.

◦Adjusted Earnings per Share is expected to be between $0.50 and $0.57 per share, now including stock-based compensation.

Atlanta, GA – February 10, 2026 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the fourth quarter and full year ended December 31, 2025.

“Mirion concluded another successful year, highlighted by record orders, strong tailwinds from key strategic end-markets, and a broadening nuclear power portfolio,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “In addition, we delivered on our Adjusted EBITDA and our Adjusted Free Cash Flow targets.”

Logan continued, “We booked over $1 billion of orders in 2025, including approximately $150 million from the large opportunity pipeline previously foreshadowed. Importantly, these orders reflect growth from all three Nuclear Power verticals: new utility scale reactors, the installed base, and small modular reactors. We continue to expect meaningful order growth in 2026, including full-year contributions from Paragon Energy Solutions and Certrec.”

2026 Guidance

Commenting on Mirion’s full year 2026 guidance, Logan said, “2026 guidance reflects strong market fundamentals supporting growing revenue, expanding margins, and enhancing Adjusted Free Cash Flow generation.”

Mirion has provided the following guidance for the fiscal year ending December 31, 2026.

•Revenue growth of approximately 22.0% – 24.0%; includes a foreign exchange rate and acquisition-related tailwinds

•Organic Revenue growth of approximately 5.0% – 7.0%

•Adjusted EBITDA of approximately $285 million – $300 million; Adjusted EBITDA margin of approximately 25.0% – 26.0%

Exhibit 99.1

News Release

•Adjusted Free Cash Flow of approximately $155 million – $175 million; Adjusted Free Cash Flow Conversion of approximately 54% – 58% of Adjusted EBITDA

•Adjusted EPS of approximately $0.50 – $0.57 per share; now including stock-based compensation

Additional modeling and guidance assumptions are included in the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for organic revenue growth, adjusted EBITDA, adjusted EPS, adjusted free cash flow and adjusted free cash flow conversion are not available without unreasonable effort.

Conference Call

Mirion will host a conference call tomorrow, February 11, 2026 at 11:00 a.m. ET to discuss its financial results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events.

A telephonic replay will be available shortly after the conclusion of the call and until February 25, 2026. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671, and e

EX-99.1

2 a2025-10x28exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Third Quarter 2025 Financial Results and Updates Full Year Guidance

•Revenue for the third quarter increased 7.9% to $223.1 million, compared to $206.8 million in the same period in 2024.

•GAAP net income was $3.1 million in the third quarter, compared to a GAAP net loss of $14.0 million in the same period in 2024; a 122% improvement. Adjusted EBITDA was $52.4 million in the third quarter, a 14.7% increase from $45.7 million in the same period in 2024.

•GAAP net earnings per share in the third quarter was $0.01, compared to a GAAP net loss per share of $0.07 in the same period in 2024. Adjusted earnings per share for the quarter was $0.12, compared to $0.08 in the same period in 2024.

•The company reaffirmed 2025 guidance for total Revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted EPS guidance while revising Adjusted Free Cash Flow for the fiscal year ending December 31, 2025, including estimated tariff impacts based on today’s levels, net of mitigating actions and updated fourth quarter foreign exchange rates.

Atlanta, GA – October 28, 2025 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the third quarter ended September 30, 2025.

“Mirion posted another strong quarter supported by the continued momentum in the nuclear power end-market,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “All key financial metrics grew in the quarter, keeping us on-track for our 2025 guidance.”

Logan continued, “We also delivered on our stated goal to broaden our exposure to favorable market tailwinds in nuclear power. In September, we announced an agreement to acquire Paragon Energy Solutions to augment our U.S. nuclear power presence with additional products, software and services. When the deal closes, it is expected to add an energetic, growing business to our nuclear portfolio. Together, with the Certrec acquisition that closed in July, our nuclear power-based revenue is expected to be approximately 45% of total revenue.”

Update on Large Opportunity Pipeline Mirion was awarded an approximately $10 million small modular reactor new build order in the third quarter 2025. Subsequently, in October 2025, Mirion was awarded an approximately $55 million order for the Asia installed base. These orders are part of the previously communicated $350 million large opportunity pipeline. Currently, there remains $285 million of previously communicated orders to be awarded. This includes $175 million of orders expected to be awarded in 2025 and $110 million of orders now expected to be awarded in 2026, due to timing.

2025 Guidance

Commenting on Mirion’s full year 2025 guidance, Logan said, “We are raising the lower end of our adjusted Free Cash Flow guidance range while reaffirming the remaining financial metrics. We are well-positioned today to deliver on our full year targets and look forward to sharing 2026 expectations in February.”

Mirion has provided the following guidance for the fiscal year ending December 31, 2025.

•Revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points.

•Organic Revenue growth of approximately 4.5% – 6.0%.

•Adjusted EBITDA of approximately $223 million – $233 million; Adjusted EBITDA margin of approximately 24.0% – 25.0%.

Exhibit 99.1

News Release

•Adjusted Free Cash Flow of approximately $100 million – $115 million (previously $95 million - $115 million); Adjusted Free Cash Flow Conversion of approximately 45% – 49% of Adjusted EBITDA (previously 43% - 49%).

•Adjusted EPS of approximately $0.48 – $0.52 per share.

Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page. Our 2025 guidance does not include any impact from the announced Paragon acquisition.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be r

EX-99.1

2 a2025-07x31exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Second Quarter 2025 Financial Results and Updates Full Year Guidance

•Revenue for the second quarter increased 7.6% to $222.9 million, compared to $207.1 million in the same period in 2024.

•GAAP net income was $8.5 million in the second quarter, compared to a GAAP net loss of $12.0 million in the same period in 2024; a 171% improvement. Adjusted EBITDA was $51.2 million in the second quarter, a 4.9% increase from $48.8 million in the same period in 2024.

•GAAP net earnings per share in the second quarter was $0.04, compared to a GAAP net loss per share of $0.06 in the same period in 2024. Adjusted earnings per share for the quarter was $0.11, compared to $0.10 in the same period in 2024.

•The company raised guidance for total Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS and revised Organic Revenue growth guidance for the fiscal year ending December 31, 2025, including estimated tariff impacts based on today’s levels, net of mitigating actions and updated full year foreign exchange rates.

Atlanta, GA – July 31, 2025 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the second quarter ended June 30, 2025.

“Our second quarter results demonstrate continued progress towards key 2025 financial targets and positively position us to capture robust market dynamics,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “Nuclear power and cancer care tailwinds remain vibrant and Mirion is better positioned than ever to capitalize on these favorable market trends. We improved our strategic positioning and operating performance while successfully minimizing our tariff exposure to date.”

Logan continued, “Meanwhile, we continue to strategically improve our business. In the second quarter, we successfully completed a $400 million convertible notes offering and refinanced our Term Loan B to further optimize our capital structure. Additionally, we announced the acquisition of Certrec to expand our services and software offerings. Certrec complements our existing nuclear power product suite while creating additional opportunities in the broader energy power markets. Together with Certrec, Mirion is a leading supplier to the nuclear power renaissance underway.”

2025 Guidance

Commenting on Mirion’s full year 2025 guidance, Logan said, “Our first half performance, foreign exchange tailwinds, and visibility for the remainder of the year give us the confidence to increase key components of our annual guidance. Notably, capital structure enhancements contributed to our increased Adjusted Free Cash Flow and Adjusted EPS guidance.”

Mirion has increased its 2025 total Revenue growth, Adjusted EBITDA (while tightening the corresponding Adjusted EBITDA margin range), Adjusted Free Cash Flow, and Adjusted EPS guidance while revising Organic Revenue growth guidance for the fiscal year ending December 31, 2025, including estimated tariff impacts based on today’s levels, net of mitigating actions and updated full year foreign exchange rates.

•Revenue growth of approximately 7.0% – 9.0% (previously 5.0% – 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points.

Exhibit 99.1

News Release

•Organic Revenue growth of approximately 5.0% – 7.0% (previously 5.5% – 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry Services end-markets expectations

•Adjusted EBITDA of approximately $223 million – $233 million (previously $215 million - $230 million); Adjusted EBITDA margin of approximately 24.0% – 25.0% (previously 24.0% – 25.5%).

•Adjusted Free Cash Flow of approximately $95 million – $115 million (previously $85 million - $110 million); Adjusted Free Cash Flow Conversion of approximately 43% – 49% of Adjusted EBITDA (previously 39% – 48%).

•Adjusted EPS of approximately $0.48 – $0.52 per share (previously $0.45 – $0.50 per share).

Additional modeling and guidance assumptions are included on slide 20 in the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such

EX-99.1

2 a2025-04x29exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces First Quarter 2025 Financial Results and Updates Full Year Guidance

•Revenues for the first quarter increased 4.9% to $202.0 million, compared to $192.6 million in the same period in 2024.

•GAAP net income was $0.4 million in the first quarter, compared to a GAAP net loss of $26.5 million in the same period in 2024; a 102% improvement. Adjusted EBITDA was $46.7 million in the first quarter, an 18% increase from $39.5 million in the same period last year.

•GAAP net earnings per share in the first quarter was $0.00, compared to a GAAP net loss per share of $0.13 in the same period in 2024. Adjusted earnings per share for the quarter was $0.10, compared to $0.06 in the same period in 2024.

•The company reaffirmed 2025 Organic Revenue growth, Adjusted EBITDA, Adjusted EPS, and Adjusted Free Cash Flow guidance while revising total revenue growth and the corresponding Adjusted EBITDA margin for the fiscal year ending December 31, 2025, including estimated tariff impacts based on today’s levels, net of mitigating actions and updated full year foreign exchange rates.

Atlanta, GA – April 29, 2025 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the first quarter ended March 31, 2025.

“We delivered a strong start to the year, with year-over-year revenue growth and adjusted free cash flow generation,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “Additionally, order entry accelerated, driven by strong demand from the nuclear power end-market. We continue to be bullish on the year, notwithstanding the impact of new prevailing tariffs and U.S. government funding reductions.”

“Both of our operating segments grew first quarter revenue compared to the prior year. This supported Adjusted EBITDA margin expansion, reflecting both operating leverage and procurement savings in the quarter.”

Logan concluded, “First quarter total orders marked an 11.5% year-over-year improvement to $203 million. Importantly, this does not include any of the potential $300 to $400 million large, one-time orders currently in the bidding process. This performance reflects the net favorable macro factors supporting growth in our business.”

2025 Guidance

Commenting on Mirion’s full year 2025 guidance, Logan said, “Our resilient business model has us on-track for 2025 Organic Revenue growth, Adjusted EBITDA, Adjusted EPS, and Adjusted Free Cash Flow guidance. We remain confident in our value creation strategy and are well-positioned for the new tariff landscape. Our regionalized supply chain is a competitive advantage in today’s uncertain trade environment and de-risks our ability to address customers’ needs.”

Mirion has reaffirmed 2025 Organic Revenue growth, Adjusted EBITDA, Adjusted EPS, and Adjusted Free Cash Flow guidance while revising total revenue growth and the corresponding Adjusted EBITDA margin for the fiscal year ending December 31, 2025, including estimated tariff impacts based on today’s levels, net of mitigating actions and updated full year foreign exchange rates.

•Revenue growth of approximately 5.0% – 7.0% (previously 4.0% – 6.0%); includes a foreign exchange rate headwind of approximately 40 basis points using a Euro-to-USD exchange rate of 1.08.

•Organic Revenue growth of approximately 5.5% – 7.5% (no change from previous guidance); includes an approximately 30 basis point lasers business closure headwind from 2024

Exhibit 99.1

News Release

•Adjusted EBITDA and Adjusted EBITDA margin of approximately $215 million – $230 million (no change from previous guidance) and 24.0% – 25.5% (previously 24.5% – 25.5%), respectively

•Adjusted Free Cash Flow of approximately $85 million – $110 million (no change from previous guidance); Adjusted Free Cash Flow Conversion of approximately 39% – 48% of adjusted EBITDA (no change from previous guidance)

•Adjusted EPS of approximately $0.45 – $0.50 per share (no change from previous guidance)

Additional modeling and guidance assumptions are included on slide 17 in the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustme

EX-99.1

2 a2025-02x11exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Record Fourth Quarter and Record Full Year 2024 Financial Results; Reaffirms Full Year 2025 Guidance

•Revenues for the fourth quarter increased 10.4% to $254.3 million, compared to $230.4 million in the same period in 2023.

•GAAP net income was $15.9 million in the fourth quarter, compared to a GAAP net loss of $14.5 million in the same period last year; a 210% improvement. Adjusted EBITDA was $69.6 million, a 14.1% increase from $61.0 million in the same period last year.

•GAAP net earnings per share in the fourth quarter was $0.07, compared to a GAAP net loss per share of $0.08 in the fourth quarter of 2023. Adjusted earnings per share for the quarter was $0.17, compared to $0.15 in the same period last year.

•The company reaffirmed its full year 2025 guidance provided at the December 2024 Investor Day for revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance and introduced Adjusted Earnings per Share guidance.

◦Total and Organic Revenue growth rates are expected to be between 4.0% to 6.0% and 5.5% to 7.5%, respectively.

◦Adjusted EBITDA is expected to be between $215 million and $230 million.

◦Adjusted Free Cash Flow is expected to be between $85 and $110 million.

◦Initial Adjusted Earnings per Share guidance is between $0.45 and $0.50 per share.

Atlanta, GA – February 11, 2025 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the fourth quarter and full year ended December 31, 2024.

“We are pleased to report record 2024 performance, with good momentum continuing into 2025,” commented Mirion’s Chief Executive Officer Thomas Logan. “Both fourth quarter and full year performance marked record revenue, record adjusted EBITDA, and record adjusted EPS all while delivering on our full year guidance. We also simplified our capital structure and significantly improved our net leverage during the year.”

Logan continued, “Our Nuclear & Safety and Medical Groups grew fourth quarter organic revenue and enhanced their adjusted EBITDA margin performance compared to the same period last year. The fourth quarter reflects continued progress towards the 2028 long-range plan introduced at our Investor Day.”

Logan concluded, “We entered 2025 with approximately half of expected 2025 revenue in our backlog. We are advancing discussions on the $300 - $400 million of large order potential previously disclosed and see increased opportunities to bid on other large deals. Moreover, short order-cycle time flow business continues to reflect positive momentum from our key vertical markets.”

2025 Guidance

Commenting on Mirion’s full year 2025 guidance, Logan said, “We are reaffirming the 2025 financial guidance that we shared at our Investor Day and are introducing adjusted EPS guidance. We are confident in our ability to continue to grow the business, deliver margin expansion, and drive greater free cash flow in 2025 and beyond.”

Mirion has provided the following guidance for the fiscal year ending December 31, 2025.

•Revenue growth of approximately 4.0% – 6.0%; includes a foreign exchange rate headwind of approximately 190 basis points

Exhibit 99.1

News Release

•Organic Revenue growth of approximately 5.5% – 7.5%; includes an approximately 30 basis point lasers business closure headwind from 2024

•Adjusted EBITDA and Adjusted EBITDA margin of approximately $215 million - $230 million and 24.5% - 25.5%, respectively; includes a foreign exchange rate headwind to adjusted EBITDA of approximately $6 million

•Adjusted Free Cash Flow of approximately $85 million - $110 million; adjusted Free Cash Flow Conversion of approximately 39% - 48% of adjusted EBITDA

•Adjusted EPS of approximately $0.45 – $0.50 per share

Additional modeling and guidance assumptions are included in the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for organic revenue growth, adjusted EBITDA, adjusted EPS, adjusted free c

EX-99.1

2 a2024-0930exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Third Quarter 2024 Financial Results and Updates Full Year Guidance

•Revenues for the third quarter increased 8.2% to $206.8 million, compared to $191.2 million in the same period in 2023.

•Net loss was $14.0 million in the third quarter, compared to a net loss of $12.9 million in the same period last year. Adjusted EBITDA was $45.7 million, a 17.8% increase from $38.8 million in the same period last year.

•Loss from operations margin was 0.8% in the third quarter, compared to 5.8% in the same period in 2023. Adjusted EBITDA margin was 22.1% in the third quarter, compared to 20.3% in the same period last year.

•GAAP net loss per share for the third quarter was $0.07, compared to $0.06 in the third quarter of 2023. Adjusted earnings per share for the quarter was $0.08, compared to $0.05 in the same period last year.

•The company updated its full year 2024 guidance. Total and organic revenue growth rates now expected to be 6% to 7% and 5% to 6%, respectively. Adjusted free cash flow range tightened to $65 to $75 million. Maintaining adjusted EBITDA and adjusted EPS range of between $195 to $205 million and $0.37 to $0.42 per share, respectively.

Atlanta, GA – October 29, 2024 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the third quarter ended September 30, 2024.

“Third quarter results were in-line with our expectations,” stated Thomas Logan, Mirion’s Chief Executive Officer. “We continue to see revenue growth and margin expansion across both segments, supported by strong underlying super-trends in nuclear power and cancer care. Moreover, excluding the impacts from two large, one-time orders in third quarter 2023, the nuclear power adjusted order book increased 12%. Encouragingly, the spate of nuclear deals announced by hyperscalers in support of the extreme power demands enabling their AI business models should accelerate the development of next-generation nuclear power technology. Our broad strategic relationships with both small modular reactor (“SMR”) players and utility-scale nuclear power providers has us well-positioned for future growth.”

Logan continued, “Adjusted EBITDA margin in the quarter was 22.1% - an improvement of approximately 180 basis points compared to the same period last year. This marks the fifth consecutive quarter of EBITDA margin expansion and reflects the continuous improvement of operating quality across the enterprise.”

Updated 2024 Guidance

Commenting on Mirion’s full year 2024 guidance, Logan said, “Our third quarter performance keeps us on-track for another strong year. Our expected 2024 performance represents improvements in top-line growth, adjusted EBITDA margin expansion, and further improvements to the balance sheet. We continue to focus on improving our operating efficiency and progressing towards our long-term stated objective of 30% adjusted EBITDA margins.”

Mirion is updating components of its guidance for the fiscal year and 12-month period ending December 31, 2024:

•Revenue growth of 6% to 7%, compared to 5% to 7% previously

◦Organic revenue growth of 5% to 6%, compared to 4% to 6% previously

▪Medical LSD organic growth, compared to LSD+ previously

▪Technologies MSD+ organic growth, which is unchanged

◦Inorganic revenue growth of approximately 1.5%, primarily as a result of the ec2 acquisition

◦Closure of lasers business expected to negatively impact organic revenue growth by approximately 30 basis points

•Adjusted EBITDA of $195 million to $205 million, which is unchanged

Exhibit 99.1

News Release

•Adjusted EPS of $0.37 to $0.42, which is unchanged

•Adjusted free cash flow of $65 million to $75 million, compared to $65 million to $85 million previously

The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures.

Other modeling and guidance assumptions include the following:

•Depreciation of approximately $34 million for the year

•Net interest expense of approximately $52 million (approximately $50 million of cash interest)

•Effective tax rate between 27% and 29%

•Capital expenditures of approximately $45 million

•Cash taxes of approximately $35 million

•Approximately 205 million shares of Class A common stock outstanding (excludes 6.8 million shares of Class B common stock, 18.8 million founder shares, subject to vesting, 1.7 million restricted stock units, 1.2 million performance stock units and a further 34.4 million shares reserved for future equity awards (subject to annual automatic increases)) (all numbers as of September 30, 2024)

•Euro to U.S. Dollar foreign exchange conversion rate of 1.09

•Cash non-operating expenses of approximately $10 million

•Stock-based compensation of a

EX-99.1

2 a2024-0630exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Second Quarter 2024 Financial Results and Updates Full Year Guidance

•Revenues for the second quarter increased 5.0% to $207.1 million, compared to $197.2 million in the same period in 2023.

•Net loss was $12.0 million in the second quarter, compared to a net loss of $28.4 million in the same period last year. Adjusted EBITDA was $48.8 million, a 10.2% increase from $44.3 million in the same period last year.

•Income (loss) from operations margin was 1.1% in the second quarter, compared to (5.4)% in the same period in 2023. Adjusted EBITDA margin was 23.6% in the second quarter, compared to 22.5% in the same period last year.

•GAAP net loss per share for the second quarter was $0.06, compared to $0.14 in the second quarter of 2023. Adjusted earnings per share for the quarter was $0.10, compared to $0.08 in the same period last year.

•The company raised its full year adjusted EBITDA guidance to $195 million to $205 million and reiterated its revenue growth guidance of 5% to 7% and adjusted EPS guidance of $0.37-$0.42.

•Signed strategic nuclear new build partnership agreement with EDF

Atlanta, GA – August 1, 2024 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the second quarter ended June 30, 2024.

“Our second quarter results were in-line with our expectations,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Both segments delivered steady top-line growth and strong Adjusted EBITDA margin expansion during the quarter. I am also pleased to announce a strategic partnership agreement that we signed with EDF, fortifying our competitive positioning in the nuclear new build market in the decades to come. We remain encouraged by the trends supporting growth in cancer care and nuclear power and I believe that the business is well-positioned for the second half of the year and beyond.”

Updated 2024 Outlook

“Looking ahead to the back half of 2024, we have reiterated our revenue growth and adjusted free cash flow expectations,” continued Mr. Logan. “Our updated Adjusted EBITDA range is reflective of strong year-to-date execution and the potential for further margin expansion the rest of the year. We continue to focus on improving our overall cash conversion dynamics and enhancing our net working capital position.”

Mirion is updating its guidance for the fiscal year and 12-month period ending December 31, 2024:

•Revenue growth of 5% - 7%, which is unchanged

◦Organic revenue growth of 4% - 6%, which is unchanged

▪Medical LSD+ organic growth, compared to MSD previously

▪Technologies MSD+ organic growth, compared to MSD previously

◦Inorganic revenue growth of approximately 1.5%, primarily as a result of the ec2 acquisition

◦Expected closure of lasers business expected to negatively impact organic revenue growth by approximately 30 basis points

•Adjusted EBITDA of $195 million - $205 million, increased from $193 million - $203 million previously

•Adjusted EPS of $0.37 - $0.42, which is unchanged

•Adjusted free cash flow of $65 million - $85 million, which is unchanged

The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures.

Other modeling and guidance assumptions include the following:

•Depreciation of approximately $34 million for the year

•Net interest expense of approximately $53 million (approximately $52 million of cash interest)

Exhibit 99.1

News Release

•Effective tax rate between 27% and 29%

•Capital expenditures of approximately $42 million

•Cash taxes of approximately $35 million

•Approximately 205 million shares of Class A common stock outstanding (excludes 6.9 million shares of Class B common stock, 18.8 million founder shares, subject to vesting, 1.8 million restricted stock units, 1.2 million performance stock units and a further 34.4 million shares reserved for future equity awards (subject to annual automatic increases)) (all numbers as of June 30, 2024)

•Euro to U.S. Dollar foreign exchange conversion rate of 1.07

•Cash non-operating expenses of approximately $10 million

•Stock-based compensation of approximately $11 million

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, mer

EX-99.1

2 a2024-0430exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces First Quarter 2024 Financial Results and Reaffirms Full Year Guidance

•Revenues for the first quarter increased 5.8% to $192.6 million, compared to $182.1 million in the same period in 2023.

•Net loss was $26.5 million in the first quarter, compared to a net loss of $42.9 million in the same period last year. Adjusted EBITDA was $39.5 million, a 7.9% increase from $36.6 million in the same period last year.

•Income from operations margin was (2.5)% in the first quarter, compared to (7.5)% in the same period last year. Adjusted EBITDA margin was 20.5% in the first quarter, compared to 20.1% in the same period last year.

•GAAP net loss per share for the first quarter was $0.13, compared to $0.22 in the first quarter of 2023. Adjusted earnings per share for the quarter was $0.06, in-line with the same period last year.

•The company reaffirmed full year 2024 guidance and continues to expect revenue growth of 5% to 7%, adjusted EBITDA of $193 million to $203 million, and adjusted EPS of $0.37-$0.42.

Atlanta, GA – April 30, 2024 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the first quarter ended March 31, 2024.

“The first quarter was a solid start for Mirion in 2024,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Revenue growth was in-line with our expectations, led by a strong quarter from our Technologies segment. I am pleased with the Adjusted EBITDA margin expansion we delivered compared to the same period last year and believe we are well-positioned heading into the rest of 2024. Engagement remains strong across our end markets and I am particularly excited by the macro trends taking shape in nuclear power and cancer care.”

Reaffirmed 2024 Outlook

“We are reaffirming our 2024 financial outlook today,” continued Mr. Logan. “I am encouraged by the commercial and operational momentum across the business and believe that we have the right strategy in place to deliver against our expectations.”

Mirion is reaffirming its guidance for the fiscal year and 12-month period ending December 31, 2024:

•Revenue growth of 5% - 7%

◦Organic revenue growth of 4% - 6%

▪Medical +MSD organic

▪Technologies +MSD organic

◦Inorganic revenue growth of approximately 1%, primarily as a result of the ec2 acquisition

◦Minimal impact from foreign exchange rates

•Adjusted EBITDA of $193 million - $203 million

•Adjusted EPS of $0.37 - $0.42

•Adjusted free cash flow of $65 million - $85 million

The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures.

Other modeling and guidance assumptions include the following:

•Depreciation of approximately $33 million for the year

•Net interest expense of approximately $55 million (approximately $52 million of cash interest)

•Effective tax rate between 26% and 28%

•Capital expenditures of approximately $40 million

•Cash taxes of approximately $35 million

Exhibit 99.1

News Release

•Approximately 204 million shares of Class A common stock outstanding (excludes 7.3 million shares of Class B common stock, 18.7 million public warrants (which were called for redemption on April 18, 2024), 8.5 million private placement warrants, 18.8 million founder shares, subject to vesting, 2.2 million restricted stock units, 1.2 million performance stock units and a further 34.3 million shares reserved for future equity awards (subject to annual automatic increases)) (all numbers as of March 31, 2024)

•Euro to U.S. Dollar foreign exchange conversion rate of 1.08

•Cash non-operating expenses of approximately $9 million

•Stock-based compensation of approximately $11 million

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for organic and inorganic revenue, adjusted EBITDA, adjusted EPS and adjusted free cash flow are not available without unreasonable effort.

Conference Call

Mirion will host a conference call tomorrow, May 1, 2024 at 9:00 a.m. ET to discuss its financial results. Particip

EX-99.1

2 a2024-028xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Guidance

•Revenues for the fourth quarter increased 5.7% to $230.4 million, compared to $217.9 million in the same period last year.

•Net loss was $15.2 million in the fourth quarter, compared to a net loss of $153.4 million in the same period last year, a 90.1% improvement. Adjusted EBITDA was $61.0 million, a 8.2% increase from $56.4 million in the same period last year.

•Net loss per share for the fourth quarter was $0.08, compared to $0.85 in the fourth quarter of 2022. Adjusted earnings per share for the quarter was $0.15, compared to $0.11 in the same period last year.

•The company initiated full year 2024 guidance for revenue growth of 5% to 7%, adjusted EBITDA of $193 million to $203 million, adjusted EPS of $0.37 to $0.42 and adjusted free cash flow of $65 million to $85 million.

Atlanta, GA – February 13, 2024 – Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the fourth quarter and full year ended December 31, 2023. Related materials will be available online at ir.mirion.com.

“2023 was an excellent year for Mirion. We delivered record revenue and adjusted EBITDA, and substantially improved cash generation and leverage,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Looking at our fourth quarter results, both business segments generated organic growth against tough comparisons from the same period last year. Customer engagement across our end markets remains strong and we enter 2024 with solid top-line coverage accruing from a record backlog position.”

2024 Outlook

“Today, we are initiating financial guidance for 2024 that reflects sustained momentum in the business,” continued Mr. Logan. “Vertical market conditions are positive, and we are well-positioned to deliver solid organic growth. We expect to expand margins and free cash flow this year, as we drive continued operational improvement across the enterprise. I am confident in our strategic positioning and believe we have the right plans in place to deliver the financial expectations we have published today.”

Mirion has issued the following guidance for the fiscal year and 12-month period ending December 31, 2024:

•Revenue growth of 5% - 7%

◦Organic revenue growth of 4% - 6%

◦Inorganic revenue growth of ~1%, primarily ec2 acquisition

◦Minimal impact from foreign exchange rates

•Adjusted EBITDA of $193 million - $203 million

•Adjusted EPS of $0.37 - $0.42

•Adjusted free cash flow of $65 million - $85 million

The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures.

Other modeling and guidance assumptions include the following:

•Depreciation of ~$33 million for the year

•Net interest expense of approximately $55 million (approximately $52 million of cash interest)

•Effective tax rate between 26% and 28%

•Capital expenditures of ~$37 million

•Cash taxes of ~$37 million

Exhibit 99.1

News Release

•Approximately 200 million shares of Class A common stock outstanding (excludes 7.8 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 1.8 million restricted stock units, 0.7 million performance stock units and a further 28.8 million shares reserved for future equity awards (subject to annual automatic increases) (all numbers as of December 31, 2023))

•Euro to U.S. Dollar foreign exchange conversion rate of 1.08

•Cash non-operating expenses of ~$9 million

•Stock-based compensation of ~$11 million

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for organic revenue growth, adjusted EBITDA, adjusted EPS and adjusted free cash flow are not available without unreasonable effort.

Conference Call

Mirion will host a conference call tomorrow, February 14, 2024, at 10:00 a.m. ET to discuss its financial results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and reque

EX-99.1

2 a2023-118xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Third Quarter 2023 Financial Results and Reiterates Full Year Guidance

•Revenues for the third quarter increased 18.8% to $191.2 million, compared to $160.9 million in the same period last year.

•Net loss was $12.1 million in the third quarter, compared to a net loss of $47.1 million in the same period last year. Adjusted EBITDA was $38.8 million, a 26.0% increase from $30.8 million in the same period last year.

•Net loss per share for the third quarter was $0.06, compared to $0.26 in the third quarter of 2022. Adjusted earnings per share for the quarter was $0.05, compared to $0.03 in the same period last year.

•The company reiterated full year 2023 guidance for revenue growth of 8% to 10%, adjusted EBITDA of $175 million to $185 million, adjusted EPS of $0.28-$0.34 and adjusted free cash flow of $45 million to $75 million.

•Closed on acquisition of ec2 Software Solutions LLC and NUMA LLC (collectively “ec2”), a leading provider of end-to-end nuclear medicine workflow software.

Atlanta, GA – November 1, 2023 – Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the third quarter ended September 30, 2023. Related materials will be available online at ir.mirion.com. On November 1, 2023, Mirion also closed the acquisition of ec2, with a purchase price of $33 million through an all cash purchase.

“This was an excellent quarter for Mirion,” stated Thomas Logan, Mirion’s Chief Executive Officer. “We delivered strong results across the business and order generation was exceptional. We exited Q3 with a record backlog position and both reporting segments delivered solid organic revenue growth. The business delivered adjusted EBITDA margin expansion compared to the same period last year and we made progress executing on our cash flow and net working capital enhancement initiatives.”

“I am proud of the team’s execution during the third quarter,” added Larry Kingsley, Chairman of Mirion’s Board. “They’ve taken a thoughtful approach to expanding margins, generating solid cash flow and deleveraging the business - and made meaningful progress on each during the third quarter. There is still work to be done, but the business has generated positive momentum heading into the fourth quarter.”

Acquisition of ec2

Headquartered in Las Vegas, NV, ec2 is a leading medical software company that designs, implements and supports comprehensive software solutions servicing the nuclear medicine space. ec2 is estimated to generate a total of $12 million in revenue and $5.5 million of proforma adjusted EBITDA for full year 2023, inclusive of pre-acquisition financial results. The ec2 team and portfolio of solutions will be integrated into Mirion’s Nuclear Medicine business unit. ec2’s portfolio of solutions will play a key role in expanding Mirion’s software offerings to Medical customers.

“I am pleased to welcome my new colleagues from ec2 to the Mirion family,” Mr. Logan said. “By adding ec2 to our Medical portfolio, we can now offer more comprehensive software solutions to our Nuclear Medicine customers, augmenting the value of our portfolio of hardware solutions in a highly complementary fashion.”

Reiterated 2023 Outlook

“Third quarter results were in-line with our expectations and position us well for a strong fourth quarter,” continued Mr. Logan. “Today, we are reiterating our financial guidance for the full year. Our focus is on commercial execution and operational excellence as we aim to meet expectations and make progress on our cash flow and margin expansion initiatives.”

Mirion is reiterating its guidance for the fiscal year and 12-month period ending December 31, 2023:

•Revenue growth of 8% - 10%

Exhibit 99.1

News Release

•Organic revenue growth of 6% - 8%

•Adjusted EBITDA of $175 million - $185 million

•Adjusted EPS of $0.28 - $0.34

•Adjusted free cash flow of $45 million - $75 million

Inorganic revenue growth is expected to be approximately 1.5%, including benefits from the SIS and ec2 acquisitions, partially offset by the Biodex rehab divestiture. Foreign exchange rates are expected to result in a positive 0.5% impact to revenue growth. The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures. This guidance includes estimates for the ec2 acquisition.

Other modeling and guidance assumptions include the following:

•Euro to U.S. Dollar foreign exchange conversion rate of 1.06

•Net interest expense of approximately $60 million (approximately $55 million of cash interest)

•Approximately 199 million shares of Class A common stock outstanding (excludes 7.8 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesti

EX-99.1

2 a2023-088xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Second Quarter 2023 Financial Results and Updates Full Year Guidance

•Revenues for the second quarter increased 12.2% to $197.2 million, compared to $175.8 million in the same period last year.

•Net loss was $28.4 million in the second quarter, compared to a net loss of 59.3 million in the same period last year. Adjusted EBITDA was $44.3 million, a 4.0% increase from $42.6 million in the same period last year.

•Net loss per share for the second quarter was $0.14, compared to $0.32 in the second quarter of 2022. Adjusted earnings per share for the quarter was $0.08, compared to $0.13 in the same period last year.

•The company updated full year 2023 guidance and now expects revenue growth of 8% to 10%, adjusted EBITDA of $175 million to $185 million, and adjusted EPS of $0.28-$0.34.

Atlanta, GA – August 2, 2023 – Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the second quarter ended June 30, 2023.

“We posted strong second quarter results, headlined by our fourth consecutive quarter of backlog expansion and solid revenue growth in both reporting segments,” stated Thomas Logan, Mirion’s Chief Executive Officer. “For the balance of the year, improving cash generation and margin expansion are my top priorities, and I believe we have the right strategy in place to improve our performance in these areas.”

“Our team delivered another solid quarter, positioning Mirion well for the second half of the year,” added Larry Kingsley, Chairman of Mirion’s Board. “We continue to see robust demand across our end markets and our order flow remains strong. The year is progressing well and we have a strong roadmap in place to deliver for our customers and our shareholders in the second half.”

Updated 2023 Outlook

“Top-line performance was very strong in the first half and we expect to see continued momentum through the remainder of the year, especially within the Technologies group,” continued Mr. Logan. “As such, we are raising and tightening our revenue growth outlook. We are also expecting Adjusted EBITDA margin improvement in the second half as mix headwinds ease, and we are working hard to improve our net working capital dynamics to drive better Adjusted Free Cash Flow conversion.”

Mirion is updating its guidance for the fiscal year and 12-month period ending December 31, 2023:

•Revenue growth of 8% - 10%, compared to 6% - 9% previously

•Organic revenue growth of 6% - 8%, compared to 4% - 7% previously

•Adjusted EBITDA of $175 million - $185 million, compared to $172 million - $182 million previously

•Adjusted EPS of $0.28 - $0.34, which is unchanged

•Adjusted free cash flow of $45 million - $75 million, compared to $58 million - $78 million previously

Inorganic revenue growth is expected to be approximately 1.0%, including benefits from the SIS acquisition, offset by the Biodex rehab divestiture, which closed early in the second quarter. Foreign exchange rates are expected to result in a positive 0.5% impact to revenue growth. The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures.

Other modeling and guidance assumptions include the following:

•Euro to U.S. Dollar foreign exchange conversion rate of 1.09

•Net interest expense of approximately $60 million (approximately $55 million of cash interest)

•Approximately 199 million shares of Class A common stock outstanding (excludes 7.8 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 2.1 million restricted

Exhibit 99.1

News Release

stock units, 0.6 million performance stock units and a further 28.7 million shares reserved for future equity awards (subject to annual automatic increases) (all numbers as of June 30, 2023))

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for adjusted EBITDA, adjusted EPS, adjusted free cash flow and net leverage are not available without unreasonable effort.

Conference Call

Mirion will host a confer

EX-99.1

2 a2023-058xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

•Revenues for the first quarter increased 11.6% to $182.1 million, compared to $163.2 million in the same period in 2022.

•Net loss was $42.9 million in the first quarter, compared to a net loss of $19.0 million in the same period last year. Adjusted EBITDA was $36.6 million, a 4.9% increase from $34.9 million in the same period last year.

•GAAP net loss per share for the first quarter was $0.22, compared to $0.10 in the first quarter of 2022. Adjusted earnings per share for the quarter was $0.06, compared to $0.10 in the same period last year.

•The company reaffirmed full year 2023 guidance and continues to expect revenue growth of 6% to 9%, adjusted EBITDA of $172 million to $182 million, and adjusted EPS of $0.28-$0.34.

Atlanta, GA – May 3, 2023 – Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the first quarter ended March 31, 2023.

During the first quarter, Mirion received a $150 million direct at-the-market investment and utilized $125 million for debt repayment. This helped the company bring net leverage down during the quarter. The company targets reducing its net leverage to 3.1x by year-end.

“The first quarter was a great start to 2023 for Mirion,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Our team delivered strong top-line growth across both business segments, producing results that were above our expectations for the quarter. As we anticipated, adjusted EBITDA margins were impacted by short-term product and geographic mix dynamics, but we expect those factors to moderate over the course of the year. Our end markets remain healthy and we are confident heading into the remainder of 2023.”

“I am pleased with the results that Mirion was able to deliver in the first quarter,” added Larry Kingsley, Chairman of Mirion’s Board. “The team has posted a solid first step toward achieving the level of growth projected for 2023 and the year has kicked off according to plan. I am particularly encouraged by the level of sustained order growth we are seeing across our end markets and the business continues to maintain a robust backlog position to fuel future growth.”

Reaffirmed 2023 Outlook

“Today, we have reaffirmed our 2023 guidance on the back of a strong first quarter,” continued Mr. Logan. “Our end markets remain supportive of our growth expectations and our teams are focused on executing upon our expectations for the remainder of the year.”

Mirion is reaffirming its guidance for the fiscal year and 12-month period ending December 31, 2023:

•Reported revenue growth of 6% - 9%

•Organic revenue growth of 4% - 7%

•Adjusted EBITDA of $172 million - $182 million

•Adjusted EPS of $0.28 - $0.34

•Adjusted free cash flow of $58 million - $78 million

Inorganic revenue growth is expected to be approximately 1.5%, including benefits from the SIS acquisition, offset by the Biodex rehab divestiture, which closed early in the second quarter. Foreign exchange rates are expected to result in a positive 0.5% impact to revenue growth. The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers and acquisitions.

Other modeling and guidance assumptions include the following:

•Euro to U.S. Dollar foreign exchange conversion rate of 1.09

•Net interest expense of approximately $60 million (approximately $56 million of cash interest)

Exhibit 99.1

News Release

•Approximately 199 million shares of Class A common stock outstanding (excludes 7.8 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 2.3 million restricted stock units, 0.6 million performance stock units and a further 28.7 million shares reserved for future equity awards (subject to annual automatic increases))

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for revenue, organic revenue, adjusted EBITDA, adjusted EPS, adjusted free cash flow and net leverage are not available without

EX-99.1

4 exhibit991-pressrelease202.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Technologies Announces $150 Million Investment from T. Rowe Price, Priced At-the-Market

•Funds and accounts advised by T. Rowe Price Investment Management, Inc. invest $150 million in Mirion to acquire 17,142,857 shares of Mirion common stock at $8.75 per share.

•Mirion intends to use approximately $125 million to pay down debt, with a target net leverage ratio of ~3.1x by the end of 2023, not inclusive of any potential M&A.

•In connection with the investment from T. Rowe Price funds and accounts and the related repayment of indebtedness, Mirion is increasing its Adjusted Free Cash Flow guidance for 2023 to a range of $58 million – $78 million.

Atlanta, GA – February 21, 2023 – Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced that it has agreed to sell $150 million of shares of Class A common stock to certain funds and accounts advised by T. Rowe Price Investment Management, Inc. (“T. Rowe Price”), a global investment management organization.

T. Rowe Price funds and accounts will acquire 17,142,857 registered shares of Mirion stock at $8.75 per share, the closing price of the company’s Class A common stock on the New York Stock Exchange on February 17, 2023. The transaction is expected to close on Thursday, February 23, 2023, subject to customary closing conditions. Mirion intends to use approximately $125 million to pay down debt, while the remaining funds of approximately $25 million (before transaction expenses) are anticipated to be used to fund organic and inorganic growth opportunities.

Thomas Logan, Mirion’s Chief Executive Officer said, “We are pleased to welcome T. Rowe Price Investment Management as a major shareholder in Mirion. This strategic investment will enable us to immediately strengthen our balance sheet through debt reduction. We expect the combined benefit of debt reduction and decreased interest expense to improve our net leverage ratio to approximately 3.1x by the end of 2023.”

The sale of shares will be made pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission (the “SEC”) on November 28, 2022. A prospectus supplement and accompanying prospectus relating to the placement will be filed with the SEC in connection with the transaction. Copies of these documents, as and when available, may be obtained, free of charge, at the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Updated 2023 Guidance

Mirion is updating its adjusted free cash flow guidance, which was previously provided on February 14, 2023, as a result of the investment and the related repayment of indebtedness. The company now expects adjusted free cash flow of $58 million – $78 million for 2023, driven by lower interest expense.

Additionally, other updated guidance assumptions include the following:

•Net interest expense of approximately $60 million (approximately $56 million of cash interest).

•Approximately 197 million shares of Class A common stock outstanding, excluding Class B shares, warrants, and profits interests.

The company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or

Exhibit 99.1

News Release

cannot be reasonably predicted. Accordingly, reconciliations of our guidance for adjusted revenue, organic adjusted revenue adjusted EBITDA, adjusted EPS and adjusted free cash flow are not available without unreasonable effort.

Exhibit 99.1

News Release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “should”, “would”, “will”, “understand” and similar words are intended to identify forward looking statements. These for

EX-99.1

2 a2023-02x148xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Technologies Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Fiscal Year 2023 Financial Guidance

•Revenues for the fourth quarter increased 22.6% to $217.9 million, compared to $177.8 million in the same period in 2021. Adjusted revenues increased 20.5% compared to the fourth quarter of 2021.

•GAAP net loss was $159.7 million in the fourth quarter. Adjusted EBITDA was $56.4 million for the same period.

•GAAP net loss per share for the fourth quarter was $0.85. Adjusted earnings per share for the same period was $0.11.

•The company initiated fiscal year 2023 guidance of 6% to 9% revenue growth, adjusted EBITDA of $172 million to $182 million and adjusted EPS of $0.28 to $0.34.

Atlanta, GA – February 14, 2023 – Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the fourth quarter and fiscal year ended December 31, 2022.

Mirion reported full year order growth for 2022 of approximately 8% compared to 2021. Backlog was $737.4 million as of December 31, 2022, reflecting 10% year-over-year growth, supported by strong engagement with the company’s diverse portfolio of solutions and supportive trends across its end markets. Order growth and backlog exclude the impact of the Hanhikivi project termination in the second quarter of 2022.

“2022 was a dynamic year for Mirion, as we completed our first full year as a public company. Our teams responded well to the myriad of challenges faced throughout the year and we delivered a strong finish to 2022,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Overall, I am very pleased with our fourth quarter results, which were highlighted by substantial revenue growth across both our reporting segments. The Medical business delivered solid top-line growth in all three e and meaningful margin expansion compared to the same period last year. Industrial took a noticeable step forward as well, supported by improved operating conditions and strong execution by our team. We exited 2022 with good momentum and the business is poised to deliver a strong 2023.”

“I am incredibly proud of the growth that Mirion delivered in the fourth quarter. End market demand remains quite healthy and the team has built a strong backlog position to support future growth,” added Larry Kingsley, Chairman of Mirion’s Board of Directors. “I believe that Mirion is well-positioned going into 2023 and beyond, supported by the company’s strategic market position and diverse portfolio of essential products and services.”

The Company recorded goodwill impairment charges of $87.3 million in its Medical segment and $69.3 million in its Industrial segment as a result of its required annual impairment test. The impairment charges represented approximately 10% of the company’s total goodwill balance as of December 31, 2022.

2023 Outlook

“Today, we are providing initial financial guidance for 2023. We are expecting to build off the momentum we established coming out of the fourth quarter,” continued Mr. Logan. “We are anticipating solid top-line growth in 2023, supported by healthy end markets and our robust backlog position. We have taken a thoughtful approach to setting our guidance and believe we have the right strategy in place to execute on our expectations.”

Mirion has issued the following guidance for the fiscal year ending December 31, 2023:

•Reported revenue growth of 6% to 9%, organic growth of 4% to 7%

•Adjusted EBITDA of $172 million - $182 million

•Adjusted EPS of $0.28 - $0.34

•Adjusted free cash flow of $50 million - $70 million

Exhibit 99.1

News Release

Organic revenue growth is expected at 4% to 7%. Inorganic revenue growth is expected to be approximately 1.5% including benefits from the SIS acquisition, offset by the Biodex physical rehab divestiture, expected to close during the first quarter. Foreign exchange rates are expected to result in a positive 0.5% impact to revenue growth. The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures. Other modeling and guidance assumptions include the following:

•Euro to U.S. Dollar foreign exchange conversion rate of 1.07

•Depreciation of approximately $30 million

•Net interest expense of approximately $68 million (approximately $64 million of cash interest)

•Capital expenditures of approximately $40 million

•Effective tax rate of between 25% and 27%

•Approximately 181 million shares of Class A common stock outstanding (excludes 8.0 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 1.7 million restricted stock units, 0.4 million performance stock units and a further 23.6 million

EX-99.1

2 a2022-11x018xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Technologies Announces Third Quarter 2022 Financial Results

•Revenues for the third quarter increased 11.5% to $160.9 million, compared to $144.3 million in the same period in 2021. Adjusted revenues increased 8.7% compared to the third quarter of 2021.

•GAAP net loss was $50.4 million in the third quarter, compared to a net loss of $46.7 million in the same period last year. Adjusted EBITDA was $30.8 million for the quarter, a 0.3% decrease from $30.9 million in the same period last year.

•GAAP net loss per share for the third quarter was $0.26. Adjusted earnings per share for the same period was $0.03.

•The company reaffirmed 2022 organic adjusted revenue growth of 4% to 6% and is now expecting adjusted EBITDA of $160 million to $170 million and adjusted EPS of $0.37 to $0.41.

Atlanta, GA – November 1, 2022 – Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the third quarter ended September 30, 2022.

Mirion reported year-to-date order growth of 23% as of September 30, 2022, compared to the same period last year. Backlog was $726 million as of September 30, 2022, reflecting 15% year-over-year growth, driven by the company’s diversified product portfolio and improving underlying market trends. Order growth and backlog exclude the impact of the Hanhikivi project termination in the second quarter of 2022.

“I am proud of our team’s efforts throughout the third quarter. The operating environment continued to be challenging, but we believe we have positioned the business well for future success,” stated Thomas Logan, Mirion’s Chief Executive Officer. “I am pleased with our order intake and the continued customer engagement we are seeing across all of our business verticals. Our Medical business posted a tremendous quarter with more than 20% organic revenue growth, supported by strength across all of our end markets. On the Industrial side, we saw strong order performance, but order timing dynamics and foreign exchange movements hindered performance.”

“The strength in demand for the solutions that Mirion provides continues to impress me,” added Larry Kingsley, Chairman of Mirion’s Board of Directors. “While execution proved to be more challenging than expected during the quarter, I believe the business is poised to deliver strong results in Q4 2022 and beyond. Tom and the team have worked tirelessly to position Mirion for success and I know they have a strong game plan in place to build on the strong momentum across the business.”

Updated 2022 Outlook

“We are updating our guidance for 2022 to reflect our third quarter performance and updated outlook for the operating environment,” continued Mr. Logan. “We are expecting a strong fourth quarter and believe that we have positioned our business well to deliver on this updated outlook.”

Mirion is updating its guidance for the year ending December 31, 2022:

•Reaffirming organic adjusted revenue growth of 4% - 6%

•Adjusted EBITDA of $160 million - $170 million

•Adjusted EPS of $0.37 - $0.41

•Adjusted free cash flow of $30 million - $45 million

Two recent acquisitions, CIRS (acquired December 2021), and the Collins Aerospace Critical Infrastructure business (acquired August 2022) are collectively expected to deliver 4.0% of inorganic revenue growth in 2022. Foreign exchange rates are now expected to result in an approximately negative 5% impact to reported adjusted revenue growth. The guidance for organic adjusted revenue growth excludes the impact of foreign exchange rates as well as mergers and acquisitions. Other modeling and guidance assumptions include the following:

Exhibit 99.1

News Release

•Euro to U.S. Dollar foreign exchange conversion rate of 1.00, versus 1.02 previously

•Net interest expense of approximately $42 million (approximately $38 million of cash interest)

•Approximately 181 million shares of Class A common stock outstanding (excludes 8.0 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 1.8 million restricted stock units, 0.4 million performance stock units and a further 23.7 million shares reserved for future equity awards (subject to annual automatic increases)), all as of September 30, 2022

The company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary f

EX-99.1

2 a2022-068xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Technologies Announces Second Quarter 2022 Financial Results and Confirms Full Year Guidance

•Revenues for the second quarter decreased 2.3% to $175.8 million, compared to $180.0 million in the same period in 2021. Adjusted revenues decreased 4.3% compared to the second quarter of 2021.

•GAAP Net loss was $59.3 million in the second quarter, compared to a net loss of $54.0 million in the same period last year. Adjusted EBITDA was $42.6 million for the quarter, a 14.6% decrease from $49.9 million in the same period last year.

•GAAP net loss per share for the second quarter was $0.32. Adjusted earnings per share for the same period was $0.13.

•The company confirmed 2022 expectations for organic adjusted revenue growth of 4% to 6%, adjusted EBITDA of $170 million to $180 million and adjusted EPS of $0.44 to $0.49.

Atlanta, GA – July 29, 2022 – Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for its fiscal quarter ended June 30, 2022.

Mirion reported order growth of 25% for the first half of 2022, compared to the same period last year. Backlog was $693 million as of June 30, 2022. Backlog grew 9% year-over-year. Order growth and backlog exclude the impact of the Hanhikivi project termination in the second quarter of 2022 and the reversal impact from MBD-2TM battlefield dosimeter in the second quarter of 2021.

“Our team was able to deliver results in line with expectations despite a dynamic operating environment during the second quarter. We were particularly encouraged by the performance of our Medical segment during the quarter and expect to add to the momentum heading into the second half of the year. In the Industrial segment, we faced continued challenges from the supply chain and our revenue mix transition in the face of strengthening demand,” stated Thomas Logan, Mirion’s Chief Executive Officer. “The strong growth in our orders is a key takeaway from the quarter, which we believe establishes the foundation for near-term and future growth.”

“I am impressed by the resiliency that Mirion continues to demonstrate quarter-after-quarter. The company has adapted well to the variety of market dynamics and market-induced operational challenges,” added Larry Kingsley, Chairman of Mirion’s Board of Directors. “The team has demonstrated the ability to pivot and deliver results regardless of external factors, which should prove to be a strong attribute amidst the evolving geopolitical and macroeconomic environment all companies generally face today. I believe that the business is well-positioned for success in the second half of 2022.”

The company recorded a goodwill impairment charge of $55 million in its Radiation Monitoring Systems (RMS) business due to the cancellation by one of RMS’s customers with a Russian state-owned entity to build a nuclear power plant in Finland (e.g. the Hanhikivi Project) as a result of the Russia-Ukraine conflict.

Updated 2022 Outlook

“We expect the strong order inflow during the first half of the year to support the attainment of our previously stated financial targets,” continued Mr. Logan. “We are focused on execution and believe the evolving market dynamics in both business segments support our guidance for the full year 2022.”

Mirion is confirming its guidance for the fiscal year and 12-month period ending December 31, 2022:

•Organic adjusted revenue growth of 4% - 6%

•Adjusted EBITDA of $170 million - $180 million

•Adjusted EPS of $0.44 - $0.49

•Adjusted free cash flow of $75 million - $95 million

Exhibit 99.1

News Release

CIRS, which was acquired in December 2021, is expected to deliver approximately 2% incremental inorganic revenue growth. Foreign exchange rates are now expected to result in an approximately negative 4% impact to reported adjusted revenue growth. The guidance for organic adjusted revenue growth excludes the impact of foreign exchange rates as well as mergers and acquisitions. Other modelling and guidance assumptions include the following:

•Euro to U.S. Dollar foreign exchange conversion rate of 1.02, versus 1.10 previously

•Net interest expense of approximately $42 million (approximately $38 million of cash interest)

•Approximately 181 million shares of Class A common stock outstanding (excludes 8.1 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 1.9 million restricted stock units, 0.4 million performance stock units and a further 23.7 million shares reserved for future equity awards (subject to annual automatic increases)), all as of June 30, 2022

The company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties a

EX-99.1

2 a2022-038xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Technologies Announces First Quarter 2022 Financial Results and Updates Full Year Guidance

•Revenues for the first quarter decreased 1.8% to $163.2 million, compared to $166.2 million in the same period in 2021. Adjusted revenues decreased by 4.3% compared to the first quarter of 2021.

•Net loss was $19.0 million in the first quarter, an improvement from a net loss of $40.7 million in the same period last year. Adjusted EBITDA was $34.9 million for the quarter, a 12.5% decrease from $39.9 million in the same period last year.

•GAAP net loss per share for the first quarter was $0.10. Adjusted earnings per share for the same period was $0.10.

•The company updated full year 2022 guidance and is now expecting organic adjusted revenue growth of 4% to 6% and adjusted EBITDA of $170 million to $180 million and adjusted EPS of $0.44-$0.49.

Atlanta, GA – May 4, 2022 – Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for its fiscal quarter ended March 31, 2022.

“Our teams responded well to the myriad of operating challenges that our company faced in the first quarter of 2022. Difficult comparisons on the industrial side of our business compared to the first quarter of 2021, continuing supply chain hurdles and customer project delays brought on by the Ukraine conflict represented headwinds during the quarter,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Despite these challenges, we continued to experience strong engagement and order inflows across our product portfolio. We remain committed to executing on our company strategy and are confident in our competitive positioning heading into the remainder of 2022 and beyond.”

“I believe that the Mirion team performed admirably as they managed through the variety of headwinds present across the company’s international operating profile,” added Larry Kingsley, Chairman of Mirion’s Board. “While challenging in the short-term, it is important to remember that this is an incredibly resilient business led by a team that has proven they can deliver in the face of a challenging operating environment. Our end markets are healthy and our team has the right strategy in place to deliver strong results for the rest of 2022.”

Updated 2022 Outlook

“Following the conclusion of our first quarter and analyzing the current global operating environment, we are updating our full year 2022 guidance,” continued Mr. Logan. “These updates reflect the removal of remaining Russian-related projects from our 2022 guidance, largely offset with new opportunities in the defense and nuclear power sectors. We don’t have the ability to project how the situation in Ukraine may affect our business in the future and felt it prudent to provide guidance that reflects current expectations.”

Mirion is now expecting the following results for the fiscal year and 12-month period ending December 31, 2022:

•Organic adjusted revenue growth of 4% - 6%, versus prior expectations of 5% - 7%

•Adjusted EBITDA of $170 million - $180 million, compared to prior guidance of $175 million - $185 million

•Adjusted EPS of $0.44 - $0.49, which is down from the previous range of $0.45 - $0.50

•Adjusted free cash flow of $75 million - $95 million, compared to prior guidance of $90 million - $110 million

CIRS is expected to deliver approximately 2% incremental inorganic revenue growth and foreign exchange rates are now expected to result in an approximately negative 2.5% impact to reported adjusted revenue growth. The guidance for organic adjusted revenue growth excludes the impact of foreign exchange rates as well as mergers and acquisitions.

Exhibit 99.1

News Release

Other modelling and guidance assumptions include the following:

•Euro to U.S. Dollar foreign exchange conversion rate of 1.10

•Net interest expense of approximately $38 million (approximately $34 million of cash interest)

•Approximately 181 million shares of Class A common stock outstanding (excludes 8.6 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 1.0 million restricted stock units, 0.2 million performance stock units and a further 24.7 million shares reserved for future equity awards (subject to annual automatic increases))

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjust

EX-99.1

2 a2021-128xkexhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Technologies Announces Results for the Fiscal Quarter and Fiscal Year Ended December 31, 2021

•Revenues for the fiscal quarter ended December 31, 2021 increased 18% to $177.8 million, compared to $150.8 million in the prior-year period. Adjusted revenues increased by 20% for the same period.

•GAAP net loss for the successor period of October 20, 2021 to December 31, 2021 was $23.0 million and for the predecessor period of July 1, 2021 to October 19, 2021 was $105.7 million.

•Adjusted EBITDA for the successor period of October 20, 2021 to December 31, 2021 was $44.5 million and for the predecessor period of July 1, 2021 to October 19, 2021 was $31.2 million.

•The company initiated calendar year 2022 guidance of 5.5% to 7.5% reported adjusted revenue growth and adjusted EBITDA of $175 million to $185 million.

Atlanta, GA – February 23, 2022 – Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for its fiscal quarter and fiscal year ended December 31, 2021.

“I am very proud of the results that our team was able to deliver for the fourth quarter and calendar year 2021. The last calendar quarter was quite eventful for Mirion. We became a publicly-traded company, completed the acquisition of CIRS and navigated a challenging operating environment punctuated by the rapid spread of the Omicron variant of COVID-19. The company was able to deliver solid growth and our recent medical acquisitions contributed to our overall performance for the quarter ended December 31, 2021,” stated Thomas Logan, Mirion’s Chief Executive Officer. “We experienced a number of supply chain challenges, specifically within our nuclear medicine business. We are working on supply chain mitigants and constantly evolving our sourcing strategies to match the dynamic operating environment. We have implemented pricing actions across our product portfolio aimed at countering inflationary impacts on our business with more to come. We feel confident in our competitive position going into 2022 and believe that our people and technology will continue to serve as differentiated advantages and help deliver growth in 2022 and beyond.”

“The Mirion team was able to deliver solid results in the face of a challenging operating environment," added Larry Kingsley, Mirion's Board Chairman. “The company is uniquely positioned as a market leader in 14 out of 17 product categories and is well-positioned to continue taking market share across the board, driven by the strength and quality of its diverse portfolio. The M&A pipeline remains healthy and the company's medical and industrial segments are benefiting from a variety of supportive macro trends. The Mirion team has an established history of delivering sustained, positive returns over the course of the company's life and I have the utmost confidence in the company's strategy and ability to capitalize on multiple operational improvement opportunities across the business.”

Outlook

“We have officially converted our fiscal year end to December 31 (from June 30 previously) and are pleased to initiate our guidance for the 12 months ending December 31, 2022. Despite the challenges we have seen and experienced as a result of the global pandemic and resulting supply chain disruptions, we continue to see positive signs in our order book, backlog and underlying market trends. Our growth forecast reflects those positive themes and is bolstered by pricing actions already executed and to be implemented. A portion of these actions are in response to the unprecedented inflation impacting the global economy," continued Mr. Logan. “We expect to deliver 100 to 200 basis points of Adjusted EBITDA margin growth in 2022, excluding incremental and ongoing public company general and administrative costs of approximately $11.5 million and the impact of the CIRS acquisition. Margin expansion is expected to be achieved through three key pillars: commercial and pricing excellence, strategic cost initiatives and discipline, and operating leverage.”

Mirion has issued the following guidance for the fiscal year and 12 month period ending December 31, 2022:

•Reported adjusted revenue growth of 5.5% to 7.5%

•Adjusted EBITDA of $175 million - $185 million

•Adjusted EPS of $0.45 - $0.50

•Adjusted free cash flow of $90 million - $110 million

Exhibit 99.1

News Release

Organic adjusted revenue growth is expected at 5% to 7%, while CIRS is expected to deliver approximately 2% incremental inorganic revenue growth. Foreign exchange rates are expected to result in a negative (approximately 1.5%) impact to reported adjusted revenue growth. The guidance for organic growth excludes the impact of foreign exchange and acquisitions.

Other modelling and guid